Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial

BACKGROUND: Treatment for adults with acute lymphoblastic leukaemia requires improvement. UKALL14 was a UK National Cancer Research Institute Adult ALL group study that aimed to determine the benefit of adding the anti-CD20 monoclonal antibody, rituximab, to the therapy of adults with de novo B-prec...

Descripción completa

Detalles Bibliográficos
Autores principales: Marks, David I, Kirkwood, Amy A, Rowntree, Clare J, Aguiar, Melanie, Bailey, Katharine E, Beaton, Brendan, Cahalin, Paul, Castleton, Anna Z, Clifton-Hadley, Laura, Copland, Mhairi, Goldstone, Anthony H, Kelly, Richard, Lawrie, Emma, Lee, SooWah, McMillan, Andrew K, McMullin, Mary Frances, Menne, Tobias F, Mitchell, Rachel J, Moorman, Anthony V, Patel, Bela, Patrick, Pip, Smith, Paul, Taussig, David, Yallop, Deborah, Alapi, Krisztina Zuborne, Fielding, Adele K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969057/
https://www.ncbi.nlm.nih.gov/pubmed/35358441
http://dx.doi.org/10.1016/S2352-3026(22)00038-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969057/
https://www.ncbi.nlm.nih.gov/pubmed/35358441
http://dx.doi.org/10.1016/S2352-3026(22)00038-2

Ejemplares similares